The Usefulness of the Metabolic Syndrome Score in Predicting the Angiographic Outcome in Patients With STEMI Treated With Primary Percutaneous Coronary Intervention

Document Type : Original Article

Authors

Cardiovascular Medicine Department, Tanta Faculty of Medicine, Egypt.

Abstract

Background: The relationship between metabolic syndrome (MS) and the MS score and the angiographic outcome of primary percutaneous coronary intervention (PPCI) for ST-segment-elevation myocardial infarction (STEMI) is still unclear. We aimed to examine the association between angiographic outcomes including angiographic no-reflow and MS.
 
Methods: We prospectively included 100 patients with STEMI treated with PPCI. Angiographic no-reflow was defined as a thrombolysis in myocardial infarction (TIMI) risk score of below 3 or a TIMI risk score of 3 with a myocardial blushing grade (MBG) of 0 to 1 in the absence of mechanical complications. MS was defined based on the National Cholesterol Education Program criteria. The MS score was defined as the number of MS components present.
 
Results: Totally, 26 patients (26%) developed no-reflow. The patients with no-reflow had a higher prevalence of MS, a higher level of triglycerides, a lower level of high-density lipoprotein, and a higher fasting blood glucose level. The fasting blood glucose level and the time from symptom onset to wire crossing were independent predictors of the no-reflow phenomenon (OR, 1.225; 95% CI, 1.105 to 2.854; P<0.001) and (OR, 1.049; 95% CI, 1.026 to 1.073; P<0.001).
There were significant negative correlations between the MS score and both the post-intervention TIMI flow grade and MBG (P<0.001 for both).
 
Conclusions: MS plays an important role in the development of no-reflow in STEMI patients treated with PPCI with significant negative correlations between the MS score and both the post-intervention TIMI flow grade and MBG. (Iranian Heart Journal 2021; 22(4): 80-89)

Keywords


  1. Ibanez et al., “2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation,” Eur. Heart J., vol. 39, no. 2, pp. 119–177, 2018.
  2. A. Kloner, C. E. Ganote, R. B. Jennings, R. A. Kloner, C. E. Ganote, and R. B. Jennings, “The ‘ No-Reflow ’ Phenomenon after Temporary Coronary Occlusion in the Dog Find the latest version : The " No-Reflow " Phenomenon after Temporary Coronary Occlusion in the Dog,” vol. 54, no. 6, pp. 1496–1508, 1974.
  3. H. Rezkalla, K. C. Dharmashankar, I. B. Abdalrahman, and R. A. Kloner, “No-reflow phenomenon following percutaneous coronary intervention for acute myocardial infarction: Incidence, outcome, and effect of pharmacologic therapy,” J. Interv. Cardiol., vol. 23, no. 5, pp. 429–436, 2010.
  4. Bouleti, N. Mewton, and S. Germain, “The no-reflow phenomenon: State of the art,” Arch. Cardiovasc. Dis., vol. 108, no. 12, pp. 661–674, 2015.
  5. Amano et al., “Plaque Composition and No-Reflow Phenomenon During Percutaneous Coronary Intervention of Low-Echoic Structures in Grayscale Intravascular Ultrasound,” Int. Heart J., vol. 57, no. 3, pp. 285–291, 2016.
  6. H. Rezkalla, R. V. Stankowski, J. Hanna, and R. A. Kloner, “Management of No-Reflow Phenomenon in the Catheterization Laboratory,” JACC Cardiovasc. Interv., vol. 10, no. 3, pp. 215–223, 2017.
  7. Kassi, P. Pervanidou, G. Kaltsas, and G. Chrousos, “Metabolic syndrome: definitions and controversies,” BMC Med., vol. 9, no. 1, p. 48, Dec. 2011.
  8. Levantesi et al., “Metabolic Syndrome and Risk of Cardiovascular Events After Myocardial Infarction,” J. Am. Coll. Cardiol., vol. 46, no. 2, pp. 277–283, Jul. 2005.
  9. Takeno et al., “Impact of Metabolic Syndrome on the Long-Term Survival of Patients With Acute Myocardial Infarction,” Circ. J., vol. 72, no. 3, pp. 415–419, 2008.
  10. Iribarren et al., “Metabolic Syndrome and Early-Onset Coronary Artery Disease,” J. Am. Coll. Cardiol., vol. 48, no. 9, pp. 1800–1807, Nov. 2006.
  11. Y. Kim et al., “Usefulness of metabolic syndrome score in the prediction of angiographic coronary artery disease severity according to the presence of diabetes mellitus: Relation with inflammatory markers and adipokines,” Cardiovasc. Diabetol., vol. 12, no. 1, 2013.
  12. D. DeBoer et al., “Independent Associations between Metabolic Syndrome Severity &amp; Future Coronary Heart Disease by Sex &amp; Race,” J. Am. Coll. Cardiol., vol. 69, no. 9, p. 1204, Mar. 2017.
  13. Thygesen et al., “Third universal definition of myocardial infarction,” Eur. Heart J., vol. 33, no. 20, pp. 2551–2567, Oct. 2012.
  14. M. Gibson et al., “Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs.,” Circulation, vol. 101, no. 2, pp. 125–30, Jan. 2000.
  15. W. van ’t Hof, A. Liem, H. Suryapranata, J. C. Hoorntje, M. J. de Boer, and F. Zijlstra, “Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group.,” Circulation, vol. 97, no. 23, pp. 2302–6, Jun. 1998.
  16. Niccoli, F. Burzotta, L. Galiuto, and F. Crea, “Myocardial No-Reflow in Humans,” J. Am. Coll. Cardiol., vol. 54, no. 4, pp. 281–292, Jul. 2009.
  17. Kirma et al., “Clinical and procedural predictors of no-reflow phenomenon after primary percutaneous coronary interventions: experience at a single center.,” Circ. J., vol. 72, no. 5, pp. 716–21, May 2008.
  18. M. Grundy et al., “Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement,” Circulation, vol. 112, no. 17. pp. 2735–2752, 25-Oct-2005.
  19. M. Lang et al., “Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiograph,” J. Am. Soc. Echocardiogr., vol. 18, no. 12, pp. 1440–1463, Dec. 2005.
  20. M. Gibson and A. Schömig, “Coronary and Myocardial Angiography: Angiographic Assessment of Both Epicardial and Myocardial Perfusion,” Circulation, vol. 109, no. 25, pp. 3096–3105, Jun. 2004.
  21. H. Choo et al., “The impact of no-reflow phenomena after primary percutaneous coronary intervention,” Coron. Artery Dis., vol. 25, no. 5, pp. 392–398, Aug. 2014.
  22. Mazhar, M. Mashicharan, and A. Farshid, “Predictors and outcome of no-reflow post primary percutaneous coronary intervention for ST elevation myocardial infarction,” IJC Hear. Vasc., vol. 10, pp. 8–12, 2016.
  23. Choo, P. Kim, K. Chang, Y. Ahn, … D. J.-C. artery, and undefined 2014, “The impact of no-reflow phenomena after primary percutaneous coronary intervention: a time-dependent analysis of mortality,” journals.lww.com.
  24. Kurtul, S. N. Murat, M. Yarlioglues, M. Duran, I. E. Celik, and A. Kilic, “Mild to Moderate Renal Impairment Is Associated With No-Reflow Phenomenon After Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction.,” Angiology, vol. 66, no. 7, pp. 644–51, Aug. 2015.
  25. Ndrepepa et al., “Predictive Factors and Impact of No Reflow After Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction,” Circ. Cardiovasc. Interv., vol. 3, no. 1, pp. 27–33, Feb. 2010.
  26. Hadadi et al., “276 Original Investigation,” 2017.
  27. Ipek et al., “CHA2DS2-VASc Score is a Predictor of No-Reflow in Patients with ST-Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Intervention,” Angiology, vol. 67, no. 9, pp. 840–845, 2016.
  28. T. H. K. A. I. U. C. Y. N. O. E. I. Turgay Celik, “Impact of metabolic syndrome on myocardial perfusion grade after primary percutaneous coronary intervention in patients with acute St elevation myocardial infarction,” Coron. Artery Dis., vol. 17, no. 4, pp. 339–343, Jun. 2006.
  29. Nakatani et al., “Clinical Impact of Metabolic Syndrome and Its Additive Effect With Smoking on Subsequent Cardiac Events After Acute Myocardial Infarction,” Am. J. Cardiol., vol. 99, no. 7, pp. 885–889, Apr. 2007.
  30. Takeno et al., “Impact of Metabolic Syndrome on the Long-Term Survival of Patients With Acute Myocardial Infarction,” Circ. J., vol. 72, no. 3, pp. 415–419, 2008.
  31. Amano et al., “Impact of Metabolic Syndrome on Tissue Characteristics of Angiographically Mild to Moderate Coronary Lesions,” J. Am. Coll. Cardiol., vol. 49, no. 11, pp. 1149–1156, Mar. 2007.
  32. Arai et al., “Volumetric analysis of coronary plaque characterization in patients with metabolic syndrome using 64-slice multi-detector computed tomography.,” Circ. J., vol. 74, no. 10, pp. 2146–51, Oct. 2010.
  33. Tartan et al., “Metabolic syndrome is a predictor for an ECG sign of no-reflow after primary PCI in patients with acute ST-elevation myocardial infarction,” Nutr. Metab. Cardiovasc. Dis., vol. 18, no. 6, pp. 441–447, 2008.
  34. Iribarren, “The metabolic syndrome is no better than its components.,” Minerva Cardioangiol., vol. 55, no. 4, pp. 487–9, Aug. 2007.
  35. Rachas et al., “Clinical usefulness of the metabolic syndrome for the risk of coronary heart disease does not exceed the sum of its individual components in older men and women. The Three-City (3C) Study,” Heart, vol. 98, no. 8, pp. 650–655, Apr. 2012.
  36. H. Gui, Y. Ling, L. Liu, J. J. Jiang, X. Y. Li, and X. Gao, “Effect of metabolic syndrome score, metabolic syndrome, and its individual components on the prevalence and severity of angiographic coronary artery disease,” Chin. Med. J. (Engl)., vol. 130, no. 6, pp. 669–677, 2017.
  37. H. Lee et al., “Influence of obesity and metabolic syndrome on clinical outcomes of ST-segment elevation myocardial infarction in men undergoing primary percutaneous coronary intervention,” J. Cardiol., 2018.
  38. F. Wiley and M. J. Carrington, “A metabolic syndrome severity score: A tool to quantify cardio-metabolic risk factors,” Prev. Med. (Baltim)., vol. 88, pp. 189–195, 2016.
  39. Y. Kim et al., “Impact of metabolic syndrome and its individual components on the presence and severity of angiographic coronary artery disease,” Yonsei Med. J., vol. 51, no. 5, pp. 676–682, 2010.
  40. B. Lovic, D. B. Djordjevic, I. S. Tasic, and I. P. Nedeljkovic, “Impact of metabolic syndrome on clinical severity and long-term prognosis in patients with myocardial infarction with ST-segment elevation,” Hell. J. Cardiol., pp. 0–5, 2018.
  41. Iwakura et al., “CLINICAL STUDIES Myocardial Infarction and Acute Coronary Syndromes Association Between Hyperglycemia and the No-Reflow Phenomenon in Patients With Acute Myocardial Infarction,” 2003.
  42. J. Gurka, Y. Guo, S. L. Filipp, and M. D. DeBoer, “Metabolic syndrome severity is significantly associated with future coronary heart disease in Type 2 diabetes.,” Cardiovasc. Diabetol., vol. 17, no. 1, p. 17, Jan. 2018.